Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months.~* MMSE score of 20 to 28 (inclusive) at baseline or an acceptable historical flortaucipir PET scan within 6 months prior to baseline that meets the central read criteria.~* Meet 18F flortaucipir PET scan eligibility criteria.~* Meet 18F florbetapir PET scan (central read) eligibility criteria.~Exclusion Criteria:~* Have a history of long QT syndrome.~* Have received treatment with a stable dose of an acetylcholinesterase inhibitor (AChEI) and/or memantine for less than 2 months before randomization.~* Contraindication to MRI.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Donanemab Monotherapy (Donanemab-M) (Type: EXPERIMENTAL): Participants received 700 milligram (mg) donanemab intravenously (IV) every 4 weeks (Q4W) x 3 doses, then 1400 mg donanemab IV Q4W for up to 72 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo IV Q4W for up to 72 weeks.
- Donanemab in Combination With LY3202626 (Donanemab-C) (Type: EXPERIMENTAL): Participants received 700 mg donanemab IV Q4W x 3 doses, then 1400 mg donanemab IV Q4W in combination with 12 mg of LY3202626 orally for up to 72 weeks.~As per protocol amendment (d) approved on Oct 9, 2018, donanemab in combination with LY3202626 (donanemab-C) arm discontinued as there was a low probability of identifying a statistically significant effect of 12mg of LY3202626 slowing cognitive decline.

Based on this trial design, predict the completion outcome and termination type (if applicable).